Joint Formulary & PAD

Rivastigmine - Dementia (Parkinson's disease)

You are here : Home > Formulary Search > Rivastigmine - Dementia (Parkinson's disease)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Capsules
  • Oral solution
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NICE
Off Label
SPC
Restrictions / Comments :
Important

In Parkinson's dementia. Off-label use.

Suitable for primary care prescribing on recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.

Reserve oral solution for patients who are unable to swallow capsules.

 

Status 2

Blue
Formulations :
  • Patches
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NICE
Off Label
SPC
Restrictions / Comments :
Important

PATCHES - In Parkinson's dementia. Off-label use.

suitable for primary care prescribing on recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.

SAFETY WARNING - patches are available as DAILY or TWICE WEEKLY but both are described in mg/24 hours. Care required to ensure that the intended patch is prescribed and dispensed.

An MHRA alert has also been issued in response to rivastigmine overdose due to multiple patch application, cutting patches and application of patches to non-recommended sites: https://www.gov.uk/drug-safety-update/rivastigmine-exelon-transdermal-patch-risk-of-medication-errors?UNLID=7961636092025721172155

Documentation

Guidelines (Local)
Guidelines - Managing non-cognitive symptoms in people living with dementia - update Oct 2025.pdf
Webpage
NICE NG97 - Dementia -assessment, management and support for patients and carers - June 2018

PAD Profile

ChemicalSubstance :
Rivastigmine
Indication :
Dementia (Parkinson's disease)
Group Name :
Keywords :
AChE Inhibitors, acetylcholinesterase inhibitors, dementia, Parkinson's dementia
Brand Names Include :
Exelon patch, Nimvastid, Almuriva, Alzest, Prometax, Voleze, Zeyzelf, Almuriva
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2
Traffic Light Entries :
2

Committee Recommendations (1)

03 Dec 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

As part of the Surrey Heartlands Joint Formulary review, the Surrey Heartlands APC approved a change in traffic light status for patients requiring treatment with rivastigmine:

  • Blue - on specialist recommendation (previously Amber with shared care for patients who were not suitable for discharge and who required ongoing follow-up with the specialist mental health team)

The prescribing of rivastigmine for patients who are not suitable for discharge can be carried out by Primary Care but, the specialist mental health team will retain responsibility for the review and follow-up of patients that continue to require specialist input.

Other Indications

Below are listed other indications that Rivastigmine is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Dementia (Parkinson's disease).